EirGenix Inc.
101, Lane 169, Kangning Street, Xizhi District
New Taipei City
22180
Tel: 886-2-7708-0123
Fax: 886-2-7708-1666
Website: http://www.eirgenix.com/
Email: service@eirgenix.com
About EirGenix Inc.
EirGenix is a contract development and manufacturing organization to provide high quality and cost-effectiveness service supporting our clients in development, analytical testing, and cGMP manufacturing of biopharmaceuticals from pre-clinical to commercial manufacturing.YEAR FOUNDED:
2012
LEADERSHIP:
CEO: Lee Cheng Liu
CFO: Cathy Yang
7 articles about EirGenix Inc.
-
EirGenix's Breast Cancer Biosimilar Receives Marketing Authorization by EC
11/23/2023
EirGenix Inc. announced that its trastuzumab biosimilar medicine which their commercial partner Sandoz plans to commercialise had received a marketing authorization from the European Commission.
-
EirGenix's Second Breast Cancer Biosimilar EG1206A Successfully Reaches Phase 1 Clinical Trial Objectives
5/2/2023
EirGenix, Inc. (6589.TT) announced on 28th of April that it has completed the phase 1 clinical trial (EGC101) of its second breast cancer biosimilar EG1206A in Europe.
-
Positive Phase III Clinical Results for EirGenix's Proposed Trastuzumab Biosimilar
3/24/2021
In a press conference today, EirGenix, Inc. (6589.TT) announced that the Phase III clinical trial (Trial No.: EGC002, NCT03433313) of its breast cancer biosimilar, EG12014 (proposed trastuzumab biosimilar, also called EGI014), has met its primary endpoint. EG12014 has shown equivalent efficacy to Herceptin® in regards to its clinical response
-
Eirgenix Receives Approval from Japan's PMDA
2/14/2020
EirGenix's World-Class Biopharmaceutical Manufacturing Facility Becomes the First of Its Kind in Taiwan to Receive Approval
-
EirGenix, Inc. Enters Into Global License Agreement for the Commercialization of its Biosimilar Drug EG12014
4/30/2019
EirGenix, Inc. announced that it has entered into a license agreement with global generic and biosimilar drug manufacturer Sandoz AG, granting an exclusive license to Sandoz for right of commercialization of EirGenix 's breast cancer biosimilar drug, EG12014 globally with the exception of Taiwan and mainland China.
-
EirGenix, Inc. Officially Opens its Doors to its New World-Class Plant for the Commercial Mass Production of Protein Drugs
1/23/2019
Today, EirGenix, Inc. (6589) held its opening ceremony to commemorate the launch of its new ‘Protein Drug Commercial Mass Production Plant’ in Hsinchu (Zhubei) Biomedical Park
-
EirGenix Scores Phase I Success For Its Leading Biosimilar Product EG12014
5/4/2017